Deberza tablets 20 mg for type 2 diabetes (tofogliflozin hydrate, CSG452, Apleway)
What are Deberza tablets 20 mg for type 2 diabetes (tofogliflozin hydrate, CSG452, Apleway)?
An active principle of Deberza tablets is tofogliflozin hydrate, a sodium/glucose cotransporter inhibitor. It inhibits high glucose-induced reactive oxygen species generation in tubular cells and glucose reabsorption in kidneys. As the result, Deberza tablets promote the excretion of glucose into urine and decrease the blood sugar level. This medicine is safe, generally well-tolerated, and effective as in monotherapy as together with other antidiabetic medicines like acarbose or voglibose.
Active principles: tofogliflozin hydrate
Amount: 100 tablets
Maker: Kowa Co., Ltd., Nagoya, Japan
Indications: type 2 diabetes mellitus
How to take
Adults should take 1 tablet once a day, before or after breakfast.
Contraindications: do not use for the following patients:
- pregnant or breastfeeding women,
- patients with ketosis, diabetic coma or precoma,
- patients with infection or injury,
- patients in the pre-/post-operative period.
These tablets may cause hypoglycemia. Take a special care when you drive a car, work at heights or operate dangerous machinery while taking this medicine.
If hypoglycemic symptoms occur while you're taking this medicine, take glucose or sugar. If you take these tablets together with an alpha-glucosidase inhibitor (acarbose, voglibose, etc.), in case of hypoglycemic symptoms take the glucose.
In some rare cases these tablets may cause urinary-tract infection or genital infection. Pay attention to any unusual symptoms and consult with the doctor if needed.
As this medicine may cause frequent urination, drink an adequate amount of fluid and pay attention to excessive decrease in body weight.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.